Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKCA

Akcea Therapeutics (AKCA) Stock Price, News & Analysis

Akcea Therapeutics logo

About Akcea Therapeutics Stock (NASDAQ:AKCA)

Key Stats

Today's Range
$18.17
$18.17
50-Day Range
$18.13
$18.17
52-Week Range
$8.00
$21.70
Volume
N/A
Average Volume
361,806 shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AKCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKCA Stock News Headlines

Arcturus Therapeutics Holdings Inc ARCT
AKCA Historical Data
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
Akcea Therapeutics Inc (AKCA)
See More Headlines

AKCA Stock Analysis - Frequently Asked Questions

Akcea Therapeutics, Inc. (NASDAQ:AKCA) issued its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.14. The firm's revenue for the quarter was down 15.9% compared to the same quarter last year.

Akcea Therapeutics (AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Advanced Micro Devices (AMD), Ciena (CIEN), Fossil Group (FOSL) and AMC Entertainment (AMC).

Company Calendar

Last Earnings
8/04/2020
Today
9/21/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKCA
CIK
1662524
Fax
N/A
Employees
248
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.48
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$40.77 million
Net Margins
-12.34%
Pretax Margin
N/A
Return on Equity
-8.94%
Return on Assets
-8.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.17
Quick Ratio
11.78

Sales & Book Value

Annual Sales
$488.54 million
Price / Sales
3.78
Cash Flow
$0.51 per share
Price / Cash Flow
35.54
Book Value
$5.78 per share
Price / Book
3.14

Miscellaneous

Outstanding Shares
101,599,000
Free Float
N/A
Market Cap
$1.85 billion
Optionable
Optionable
Beta
1.45
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AKCA) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners